Gimv Exits Biolam To Its Management Backed By Investors
Gimv NV GIMB:
EXITS BIOLAM TO ITS MANAGEMENT BACKED BY INVESTORS AFTER A FAST AND SUCCESSFUL GROWTH TRAJECTORY INTO A LEADING FRENCH GROUP OF CLINICAL TESTING LABS
TRANSACTION HAS NO SIGNIFICANT IMPACT ON THE NET ASSET VALUE OF GIMV AS OF 30 SEPTEMBER 2022
NO FURTHER FINANCIAL DETAILS WILL BE DISCLOSED